Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OP-101 safety and PK in healthy volunteers
NCT04321980Phase 1Completed
- Sponsor
- Orpheris, Inc.
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of N-acetyl cysteine dendrimer conjugate in cerebral adrenoleukodystrophy (CALD) and neuroinflammation (2 cohorts), sponsored by Orpheris, Inc. Primary endpoint: Treatment Emergent Adverse Events. Started Mar 2020; status: completed.
02
Drugs
N-acetyl cysteine dendrimer conjugate
03
Conditions
cerebral adrenoleukodystrophy (CALD)neuroinflammation
Beyond the preview
Go deeper on NCT04321980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321980.